Report In the last ten years, biomedical scientists at universities, colleges and private laboratories have developed techniques to correct the mistakes and harms of DNA molecules copied from DNA. In 2018, Mexico was the first country in the world to accept the use of a new type of "blood medicine" called "Chronic Lymphocytic Leukemia".
DNA or deoxyribonucleic acid is a molecule in all living organisms, plants or animals. When each cell is copied and copied every time it is dying, DNA will be copied to the original cell and moved to a new cell. But in the case of copying, there may be serious and deadly diseases such as different types of cancers.
In the last ten years, biomedical scientists at universities, colleges and private laboratories have developed techniques to correct the mistakes and harms of DNA molecules copied from DNA.
We must remember that it is a molecule made up of two long threads that bind the DNA bond, that is, step by step, the appearance of a painter's stairs. When a step is broken by a bank or one step from one order to another – known as translocation – problems arise. Using an analogy, we can say that the DNA is a thread, but the golf club is less than the hair and each cell has the same nuclide.
She has recently worked on molecular medicine at the High Precision Medicine magazine, which has opened a new field of pharmacology, including medicines already produced in hospitals around the world, including Mexico, to stop the multiplication of cancer cells in the bloodstream and lungs between tissues.
A new, "revolutionary", DNA-solvent repair technique, based on the biochemical digestion CRISPR-Cas9, is used in Chinese, US and Korean laboratories. In human embryos to repair genomic damage that causes pulmonary cancer and cardiac malformation. This technique is not yet available for commercialization, but its tests are progressing rapidly.
In 2015, the Swedish Academy of Sciences awarded the Nobel Prize in Medicine, separately, how the cell works at molecular level to repair DNA damage. Every day they showed the processes of repairing damages within the human body and in the plants and animals of the body. However, when the repair mechanism fails, different illnesses appear.
These pioneering discoveries of DNA repair mechanisms are Tomas Lindahl, Paul Modrich and Aziz Sancar. His studies began decades ago, but now his products begin to make people hoping.
PRIORITY OF THE POWDER. In 2018, Mexico first approved the use of a type of "precision medicine" type of therapy called "Lymphocytic Lymphocytic Chronic Lymphocytic Lymphocyte" (CLL) type of therapy.
The new treatment, approved by the Mexican health authorities last week and the US government one week later, on June 7, is an innovation that addresses the molecular defect that prevents the death of cancer cells. In a particular study or in the "sensor" of "patient cells", treatment is precision medicine.
Authorization for the use of this Mexican treatment was granted to the Federal Protection Commission for Sanitation Risk (Cofepris) and biotechnology laboratories AbbVie Mexico, which made a multinational MURANO research to protect the action of the new treatment.
Chronic lymphocytic leukemia (CLL) is a cancer of the bone marrow and slow blood pressure. White blood cells called lymphocytes become cancerous and abnormally multiply. It is one of the most common types of adult leukemia, with leukemia having a percentage of 30 percent, compared to men who have twice as much prevalence.
As a result of the death of patients in cells, it represents chemotherapy to eradicate cancer cells, which has adverse effects. This therapy was presented on June 5 in Chicago, the American Cancer Society and Oncology Association (ASCO).
Although it seems strange, the problem underlying the different types of cancer is that cells never appear. Each healthy cell has a life style and after completing the cycles, growth and reproduction must die, but the cancer cells have a genetic information error, since the instructions for killing have disappeared.
Thus, a cell does not die, that is, when the process called apoptosis does not occur, it causes large reproduction and tumors. When an organ passes through different bodies and scattered or emitted in different parts of the body, it is called metastatic.
Precision medicine addresses the molecular defect, prevents the death of the cells and seeks to return the original apoptosis or cell death after completing the whole life cycle.
In June, Dr. Eduardo Edmundo Reynoso Gómez explained that he specializes in hematology at the Spanish Hospital chronicle New treatments to help people with CLL increase their illness, with no more serious illness, compared to standard immunotherapy of chemotherapy, which offers healing and fixed hours, but with greater toxicity.
BRAKE LUNG CANCER. Another high-quality medical device already offers benefits to extend the life of patients diagnosed with pulmonary cancer. They survive for two to four months and today DNA copies can be treated with this type of medication that corrects disturbances caused by mistakes, which are intended to increase the average survival rate of 18 months, but in the case of documented cases, patients do not last for three months. or four years.
In some cases, the same geographic region in Mexico, presented by the oncologists of Argentina and Costa Rica, on the Pfizer Latin American Seminar on Lung Cancer, in the month of Buenos Aires.
There, the message was to be optimistic for the fight against lung cancer, but it must be taken into account that not all patients have medicine and most of the patients in Latin America diagnose their lung cancer. It is already incurable.
"The strongest change has taken place in the relief of these patients. In the last four years, the recognition and use of a new treatment group are called precision drugs, which can lead to genetic mutations, lung tumors," he explained chronicle Dr. Luis Corrales, Cancer Research and Management Center, Oncologist, San José, Costa Rica.
"Mutations occur when some genes change in location or change in chromosomes (which are in the nucleus of each cell). These changes cause some protein in the membrane of the cell and act as a biochemical receptor. If these proteins are bad, & # 39; n & # 39; They stop and the cells send signals to stop them without stopping, that is, how tumors develop, which is why new drugs that lead to genetic mutation are interrupted by mixed signals called non-control cells, "said Costa Rican experts.
The most important medical message in the most important meeting was: "Before performing chemotherapy for lung cancer, a molecular study should be performed", as patients who do not treat chemotherapy and who do it. Patients with pulmonary cancer may use medications that target genetic changes without the use of standard chemotherapy.
"We are focusing on a strategy or treatment paradigm," said Dr. Diego Kaen, Director of Oncology at the University Hospital of La Rioja, University of Rioja.
"Treatments used to treat mutations are those that cause cell-mediated activity of both proteins and are called EGFR and ALK +. They cause two-cell multiplication and, if directed, it reduces tumors and improves the patient's quality of life," said Dr. Kaen, This change began in 2014.
"There are currently 3 and a half patients who have been in lung cancer for four years. The average survival is 18 months, but only 4 months before they were remanded and physicians sent home to repair and kill their legal and family affairs," he said Dr. himself, head of research center at the clinical center, Oncológico Riojano Integral (CORI).
Gene edition. In addition to the Great Precision Medicine, in the last two years, there has been a spectacular news about the world of basic science of solving DNA errors, called "genre edition".
This technology will be explained in the lies that will be cut into a specific part of the DNA molecule that we want to correct or edit the arrows. These arrows are a molecule called CRISPR-Cas9.
In this genre edition, the wrong is cut, but nothing external is associated; When the cuts occur, the DNA repair response is activated in the operation site.
Genesis, a new genome called "editing genome," was successfully tested on October 28, 2001, in China, where lung cancer patients were successfully treated with edited cells.
At that time, the CRISPR-Cas9 therapeutic commercial landscape was not challenged against the US patents rights regarding genetic editing techniques. The problem is stuck in the United States Patent and Trademark Office, it is the duty of the one who first invented the technique.
However, technology has been committed to the laboratory and, one year later, on May 2, 2017, a major historical benefit of science, the United States, China and South Korea researchers led the hereditary disease for embryonic strain for the first time thanks to the use of the same genetic editing technique .
With her work, a hypertrophic cardiomyopathy that is suffering from a 500 people leads a gene that causes pathology and is one of the most common cause of sudden death in the athletes.
In order to carry out experiments, a donor created by treating sperm healthy sperm causes a mutation of the MYBPC3 gene that causes the disease.